Title: Mitochondrial-Encoded Peptide MOTS-c is an Exercise-Induced Regulator of Aging
 Metabolic Homeostasis and Physical Capacity

- 3
- 4
- 5 Authors: Joseph C. Reynolds¹, Rochelle W. Lai¹, Jonathan S.T. Woodhead^{5,6}, James H. Joly⁴,
- 6 Cameron J. Mitchell^{7,9}, David Cameron-Smith⁷, Ryan Lu¹, Pinchas Cohen^{1,2}, Nicholas A.

7 Graham^{2,4}, Bérénice A. Benayoun^{1,2,3}, Troy L. Merry^{5,6}, Changhan Lee^{1,2,8}*.

- 8
- ⁹ ¹ Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA
 90089.
- ² USC Norris Comprehensive Cancer Center, Los Angeles, CA 90089.
- ³ USC Stem Cell Initiative, Los Angeles, CA 90089.
- ⁴ USC Mork Family Department of Chemical Engineering and Materials Science, Los Angeles,
- 14 CA 90089.
- ⁵ Discipline of Nutrition, Faculty of Medical and Health Sciences, The University of Auckland,
 Auckland, New Zealand
- ⁶Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland,
- 18 New Zealand
- ⁷ Liggins Institute, The University of Auckland, Auckland, New Zealand
- ⁸Biomedical Science, Graduate School, Ajou University, Suwon 16499, Korea.
- ⁹ School of Kinesiology, University of British Colombia, Vancouver, BC, Canada V6T 1Z3
- 22
- 23 *corresponding author: changhan.lee@usc.edu
- 24
- 25
- 26
- 27
- 28
- 29

30 Abstract:

Healthy aging can be promoted by enhancing metabolic fitness and physical capacity (1, 2). 31 32 Mitochondria are chief metabolic organelles with strong implications in aging (3-8). In addition to their prominent role in bioenergetics, mitochondria also coordinate broad physiological functions 33 by communicating to other cellular compartments or distal cells using multiple factors (9, 10), 34 including peptides that are encoded within their own independent genome (11, 12). However, it is 35 unknown if aging is actively regulated by factors encoded in the mitochondrial genome. MOTS-c 36 is a mitochondrial-encoded peptide that regulates metabolic homeostasis (13, 14), in part, by 37 translocating to the nucleus to regulate adaptive nuclear gene expression in response to cellular 38 stress (15-17). Here, we report that MOTS-c is an exercise-induced mitochondrial-encoded peptide 39 that significantly enhanced physical performance when administered to young (2 mo.), middle-40 aged (12 mo.), and old (22 mo.) mice. In humans, we found that endogenous MOTS-c levels 41 significantly increased in response to exercise in skeletal muscle (11.9-fold) and in circulation 42 (1.5-fold). Systemic MOTS-c treatment in mice significantly enhanced the performance on a 43 treadmill of all age groups (~2-fold). MOTS-c regulated (i) nuclear genes, including those related 44 45 to metabolism and protein homeostasis, (ii) glucose and amino acid metabolism in skeletal muscle, and (iii) myoblast adaptation to metabolic stress. Late-life (23.5 mo.) initiated intermittent MOTS-46 c treatment (3x/week) improved physical capacity and trended towards increasing lifespan. Our 47 data indicate that aging is regulated by genes that are encoded not only in the nuclear genome (18, 48 49 19), but also in the mitochondrial genome. Considering that aging is the major risk factor for multiple chronic diseases (20, 21), our study provides new grounds for further investigation into 50 mitochondrial-encoded regulators of healthy lifespan. 51

- 52
- 53

54 Main Text:

Organismal fitness requires continuous adaptive cellular stress responses to the ever-shifting internal and external environment. The capacity to maintain metabolic homeostasis declines with age, which impedes parenchymal function and ultimately diminishes physical capacity. Mitochondria not only produce the bulk of cellular energy, but also coordinate adaptive cellular homeostasis by dynamically communicating to the nucleus (9) and other subcellular compartments 60 (22). Mitochondrial communication is mediated by multiple nuclear-encoded proteins, transient
 61 molecules, and mitochondrial metabolites (23).

Mitochondria possess a distinct circular genome that has been traditionally known to host only 13 62 63 protein-coding genes. However, short open reading frames (sORFs) encoded in the mitochondrial genome have been recently identified. Such sORFs produce bioactive peptides, collectively 64 65 referred to as mitochondrial-derived peptides (MDPs), with broad physiological functions (11, 12). MOTS-c (mitochondrial ORF of the 12S rDNA type-c) is an MDP that promotes metabolic 66 67 homeostasis, in part, via AMPK (13, 14) and by directly regulating adaptive nuclear gene expression following nuclear translocation (15, 16). MOTS-c expression is age-dependent and 68 69 detected in multiple tissues, including skeletal muscle, and in circulation (13, 14, 24), thus it has been dubbed a "mitochondrial hormone" (14) or "mitokine" (25, 26). In fact, systemic MOTS-c 70 71 treatment reversed diet-induced obesity and diet- and age-dependent insulin resistance in mice (13). We tested if MOTS-c functions as a mitochondrial-encoded regulator of physical capacity 72 and performance (2, 27, 28) in young (2 mo.), middle-aged (12 mo.), and old (22 mo.) mice. 73

To determine if endogenous MOTS-c responds to physical exertion, and thus may be involved in 74 driving adaptation to enhance physical capacity, we collected skeletal muscle and plasma from 75 sedentary healthy young male volunteers (24.5 ± 3.7 years old and BMI 24.1 ± 2.1) that exercised 76 on a stationary bicycle (Fig. 1A). Samples were collected before, during (plasma only), and after 77 exercise and following a 4-hour rest. Western blotting revealed that endogenous MOTS-c levels 78 in skeletal muscle significantly increased after exercise (11.9-fold) and remained elevated after a 79 4-hour rest (18.9-fold) (Fig. 1B, C). ELISA revealed that circulating endogenous MOTS-c levels 80 81 also significantly increased during (1.6-fold) and after (1.5-fold) exercise, which then returned to 82 baseline after 4 hours of resting (Fig. 1D, fig. S1). These findings suggest that exercise induces the expression of mitochondrial-encoded regulatory peptides in humans. 83

We next probed if MOTS-c functions as an exercise-induced mitochondrial signal that improves physical capacity by treating young mice (CD-1; outbred) daily with MOTS-c [5mg/kg/day; intraperitoneal injections (IP)] for 2 weeks. The rotarod performance test, whereby mice are placed on a rotating rod, revealed that daily MOTS-c significantly improved physical capacity (fig. S2A), but not grip strength (fig. S2B) in young mice. Because the rotarod test can also be affected by cognitive capacity, we assessed learning and memory using the Barnes maze and found noimprovement (fig. S2C, D).

A treadmill running test confirmed that MOTS-c treatment can enhance physical performance. 91 92 Because MOTS-c is regulator of metabolic homeostasis that prevented high-fat diet (HFD)induced obesity and insulin resistance (13), we tested if MOTS-c also improved running 93 94 performance under metabolic (dietary) stress. We fed young mice (CD-1) a HFD (60% calories from fat) and treated them with 2 doses of MOTS-c (5 and 15 mg/kg/day; IP) (fig. S3A). Mice on 95 96 the higher dose of MOTS-c showed significantly superior running capacity following 10 days of treatment (Fig. 2A-C), but not 7 days of treatment (fig. S4A). We progressively increased the 97 98 treadmill speed to test both endurance and speed. The final stage, which required mice to sprint (23m/s), was reached by 100% of mice on the higher dose of MOTS-c, but only 16.6% in the lower 99 100 dose and control (vehicle) groups (Fig. 2D). Body composition analysis using a time-domain NMR analyzer revealed that both doses of MOTS-c significantly retarded fat gain and that the high dose 101 significantly increased lean mass in young mice (CD-1) (fig. S5A-C), in accord with prior reports 102 (13). 103

In young CD-1 mice, we simultaneously initiated MOTS-c treatment and a HFD (fig. S3A). To 104 test if MOTS-c can improve physical performance in mice that have been on a HFD, we fed young 105 C57BL/6J mice a HFD, or a normal diet, for 2 weeks before initiating daily MOTS-c injections 106 (15 mg/kg/day) for 2 weeks prior to a treadmill running test (fig. S3B). MOTS-c treatment 107 significantly enhanced running performance on the treadmill regardless of the diet (Fig. 2E-G, fig. 108 S4B). MOTS-c treatment enabled 25% of the young C57BL/6J mice to enter the final running 109 110 stage (highest speed) on a normal diet, but none on a HFD (Fig. 2H). Consistent with our prior 111 study (13), MOTS-c treatment curbed HFD-induced weight gain in C57BL/6J mice (fig. S5D), which was largely driven by reduced fat accumulation (fig. S5E), but not loss of lean mass (fig. 112 113 S5F), as determined by an NMR-based body composition analysis. Further, targeted metabolomics 114 revealed that MOTS-c treatment significantly regulated (i) glycolysis/PPP (pentose phosphate pathway) and (ii) amino acid metabolism (Fig. 2I, fig. S3B) in skeletal muscle, but not in liver, 115 consistent with our previous study (13). Together, these data indicate that MOTS-c treatment can 116 improve overall physical performance, in part, by targeting skeletal muscle metabolism in young 117 mice. 118

Aging is accompanied by a progressive decline in mitochondrial function (1, 8) and loss of 119 metabolic homeostasis, in which MOTS-c may play a role (2, 9). Aging is associated with reduced 120 MOTS-c levels in certain tissues, including the skeletal muscle, and in circulation (13, 24). We 121 previously showed that an acute one-week MOTS-c treatment reversed age-dependent insulin 122 resistance in mouse skeletal muscle (13). Thus, we investigated if promoting metabolic 123 homeostasis by MOTS-c treatment could reverse age-dependent decline in physical capacity. 124 Middle-aged (12 mo.) and old (22 mo.) C57BL/6N mice were treated daily with MOTS-c (15 125 mg/kg/day; IP) for 2 weeks, then subjected to a treadmill running test (Fig. 3A). Both middle-aged 126 and old mice ran significantly longer following MOTS-c treatment (Fig. 3B). Old mice ran longer 127 (2-fold) (Fig. 3C) and farther (2.16-fold) (Fig. 3D) when treated with MOTS-c. Further, MOTS-c 128 enabled 17% of the old mice to enter the final running stage (highest speed), whereas none in the 129 130 untreated group were successful (Fig. 3E). Notably, MOTS-c treatment enabled old mice to outperform untreated middle-aged mice, suggesting a more pervasive physical re-programming 131 rather than just rejuvenation. Respiratory exchange ratio (RER), measured using a metabolic cage, 132 indicates fuel preference (1.0: carbohydrates, 0.7: fat). "Metabolic flexibility", which refers to the 133 134 overall adaptive capacity to a shift in metabolic supply-demand equilibrium (e.g. exercise), declines with age (29, 30). Indeed, old mice relied on carbohydrates regardless of the time of day 135 136 (Fig. 3F), whereas middle-aged mice, and MOTS-c-treated old mice, exhibited a circadiandependent shift in fuel usage that favored fat during the daytime (Fig. 3F), coinciding with the 137 138 low-feeding hours (fig. S6). Metabolomic analysis on skeletal muscle collected immediately postexercise (a 30-minute run at a fixed moderate speed) in MOTS-c-treated (2 weeks) mice revealed 139 140 that MOTS-c significantly regulated glycolysis and amino acid metabolism (Fig. 3G); the skeletal muscles of non-exercised mice did not show significant alterations in response to MOTS-c (fig. 141 142 S7), suggesting that MOTS-c induces an adaptive metabolic response to exercise. To begin to 143 understand the molecular mechanisms underlying the effects of MOTS-c, we performed RNA-seq analysis on the same skeletal muscles used for metabolomics. Although individual-to-individual 144 variability was high, Gene Set Enrichment Analysis (GSEA) using the KEGG pathway database 145 revealed that MOTS-c regulated processes related to (i) metabolism, including those known to be 146 147 regulated by MOTS-c (e.g. AMPK signaling, glycolysis, and central carbon metabolism) (13, 15), and (ii) longevity (FDR < 15%; select pathways in Fig. 3H; full analysis in able S1). Gene 148 Ontology Biological Process (GO BP) analysis revealed a broader range of processes, including 149

metabolism (lipid, carbohydrate, amino acid, and nucleotides), oxidative stress response, immune 150 response, and nuclear transport (FDR < 15%; select pathways in fig. S8; full analysis in table S2), 151 152 again, consistent with our previous studies (13, 15). The rotarod performance test confirmed that MOTS-c treatment improved physical capacity in old mice (fig. S9A), while learning and memory 153 was not affected as determined using the Y-maze test (fig. S9B), consistent with our observations 154 in young mice (fig. S2). Together, these data suggest that MOTS-c treatment can significantly 155 improve physical capacity in old mice, in part, by regulating skeletal function and improving 156 "metabolic flexibility". 157

Age is the major risk factor for many chronic diseases and interventions that delay aging may 158 159 extend healthy lifespan (20, 31-33). Anti-aging interventions that are applied later in life would be more translationally feasible compared to life-long treatments (34, 35). Building on the treadmill 160 161 running tests, we tested if a late-life initiated (~24 mo.) intermittent (LLII) MOTS-c treatment (3x/week; 15mg/kg/day) would improve healthy lifespan (Fig. 3A). To assess healthspan, towards 162 the end-of-life (>30 mo.), we performed a battery of physical tests to further probe the effect of 163 MOTS-c on reversing age-dependent physical decline (Fig. 3A). LLII MOTS-c improved (i) grip 164 165 strength (Fig. 4A), (ii) gait, assessed by stride length (Fig. 4B), and (iii) physical performance, 166 assessed by a 60-second walking test (running was not possible at this age) (Fig. 4C). In humans, reduced stride length and walking capacity are strongly linked to mortality and morbidity (36). 167 Together, these data indicate that LLII MOTS-c treatment improves physical capacity in old mice. 168

Independent lines of research have shown that MOTS-c is a mitochondrial-encoded metabolic 169 regulator at the cellular and organismal level (13, 15, 24, 37-41). We posited that LLII MOTS-c 170 171 treatment would cause metabolic reprogramming in old mice. Consistent with our previous report 172 (13), non-fasting blood glucose was better maintained in LLII MOTS-c-treated old mice (30 mo.; Fig. 4D). Over course of their life, LLII MOTS-c-treated mice showed comparable body weight 173 174 to their untreated counterparts (Fig. 4E, F) However, total food intake was significantly reduced 175 (Fig. 4G, H, fig. S6), whereas total activity was significantly higher (fig. S10). Body composition analysis using a time-domain NMR analyzer revealed significant reduction of fat mass (Fig. 4I, J) 176 and a modest increase in lean mass (Fig. 4K, L). The RER, measured using metabolic cages, at 30 177 178 mo. revealed increased fat utilization, consistent with that obtained at ~23.5 mo. (Fig. 3F), but with 179 a circadian shift (fig. S11); this is also consistent with reduced total fat mass (Fig. 4I, J, fig. S5B,

E) and increased lipid utilization (13, 41). Ultimately, LLII MOTS-c treatment showed a trend towards increased median (6.4%) and maximum (7.0%) lifespan and reduced hazard ratio (0.654); P=0.05 until 31.8 months (Fig. 4M). Larger cohorts will be needed to confirm the broader significance of MOTS-c treatment on overall longevity. These data suggest that LLII MOTS-c treatment improves overall physical capacity in old mice and may compress morbidity and increase healthspan.

Skeletal muscle must adapt to various exercise-induced challenges (42), including nutrient (e.g. 186 187 metabolic supply-demand imbalance) (43), oxidative (44, 45), and heat stress (42, 46), which share mitochondria as a common denominator. Because MOTS-c enhanced cellular resistance against 188 189 metabolic/oxidative stress (15), we tested if MOTS-c treatment improved skeletal muscle adaptation to metabolic stress using C2C12 mouse myoblast cells. Using crystal violet staining to 190 191 determine cellular viability, we found that MOTS-c (10µM) treatment significantly protected C2C12 cells (~2-fold) from 48 hours of metabolic stress [glucose restriction (GR; 0.5 g/L) and 192 193 serum deprivation (SD; 1% FBS)] (Fig. 5A). Next, we tested the replicative capacity of C2C12 cells following prolonged metabolic stress as a functional marker of protection. C2C12 cells were 194 195 metabolically stressed (GR/SD) for one week with daily MOTS-c (10µM) treatment, then 196 replenished with complete medium for 2 days and stained with crystal violet. MOTS-c-treated C2C12 cells showed significantly enhanced proliferative capacity within 2 days (~6-fold) (Fig. 197 5B). Because MOTS-c promotes fat utilization, which may underly its effect on "metabolic 198 199 flexibility" (Figs. 3F, 4I, J, fig. S5) (13, 41, 47), we tested if MOTS-c-treated C2C12 cells could 200 survive on lipids without glucose (0 g/L). As expected, most control cells died without glucose even with lipid supplementation, whereas MOTS-c treatment provided significant protection (~2-201 202 fold) (Fig. 5C). Real-time metabolic flux analysis revealed that MOTS-c treatment significantly increased lipid utilization capacity (Fig. 5D) and lipid-dependent glycolysis (fig. S12) in C2C12 203 204 cells.

We previously reported that endogenous MOTS-c translocates to the nucleus to directly regulate adaptive nuclear gene expression in response to cellular stress (*15*). Using fluorescently labeled MOTS-c peptide (MOTS-c-FITC), we confirmed that exogenously treated MOTS-c also dynamically translocated to the nucleus in a time-dependent manner (Fig. 4E) (*15*), indicating a direct nuclear role. We performed RNA-seq on C2C12 cells treated with MOTS-c or vehicle

control (10 μ M) under GR/SD for 48 hours and found (i) clustering by treatment type using a 210 principal component analysis (PCA) (Fig. 5F) and (ii) 69 genes that were differentially regulated 211 212 at FDR < 5% (Fig. 5G). Further, using the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database to assess putative changes in protein-protein interaction networks based 213 on our RNA-seq results, we found that a cluster related to heat-shock responses were prominently 214 regulated by MOTS-c in C2C12 cells under GR/SD; we also identified previously reported MOTS-215 c targets, including Atf3, Jun, Fosl1, and Mafg (15) (Fig. 5H). Consistently, select GO BP analysis 216 revealed protein regulation as a major target process of MOTS-c in myoblasts (select terms in fig. 217 S13; full results in table S3). To identify common pathways in *in vitro* and *in vivo* models, we 218 overlaid RNA-seq data from MOTS-c-treated (i) old mouse skeletal muscle and (ii) metabolically 219 stressed (GR/SD) C2C12. Select GO BP analysis revealed several commonly targeted processes, 220 including protein regulation, cellular metabolism, oxidative stress response, and nuclear transport 221 (select terms in Fig. 5I; full results in table S4). Together, these data suggest that MOTS-c 222 improves metabolic homeostasis/flexibility and protein homeostasis in skeletal muscle under 223 exercise-induced stress conditions. 224

Our study shows that exercise induces mtDNA-encoded MOTS-c expression. MOTS-c treatment significantly (i) improved physical performance in young, middle-aged, and old mice, (ii) regulated skeletal muscle metabolism and gene expression, and (iii) enhanced adaptation to metabolic stress in C2C12 cells. Thus, it is plausible that the physiological role of exercise-induced MOTS-c is to promote adaptive responses to exercise-related stress conditions (*e.g.* metabolic imbalance and heat shock) in the skeletal muscle and maintain cellular homeostasis.

Mitochondria are strongly implicated in aging at multiple levels (1, 2, 6-8, 48). Here, we present 231 232 evidence that the mitochondrial genome encodes for instructions to maintain physical capacity (*i.e.* performance and metabolism) during aging and thereby increase healthspan. MOTS-c treatment 233 234 initiated in late-life, proximal to the age at which the lifespan curve rapidly descends for 235 C57BL/6N mice, significantly delayed the onset of age-related physical disabilities, suggesting "compression of morbidity" in later life (49). Interestingly, an exceptionally long-lived Japanese 236 population harbors a mitochondrial DNA (mtDNA) SNP (m.1382A>C) that yields a functional 237 238 variant of MOTS-c (50, 51).

Our study shows that exogenously treated MOTS-c enters the nucleus and regulates nuclear gene expression, including those involved in heat shock response and metabolism. Thus, age-related gene networks are comprised of integrated factors encoded by both genomes, which entails a bigenomic basis for the evolution of aging. Although the detailed molecular mechanism(s) underlying the functions of MOTS-c is an active field of research, we provide a "proof-ofprinciple" study that realizes the mitochondrial genome as a source for instructions that can regulate physical capacity and healthy aging.

246

247

248 Materials and Methods

249 <u>Mouse Care</u>

250 All animal work was performed in accordance with the University of Southern California (USC) 251 Institutional Animal Care and Use Committee. MOTS-c (New England Peptide, USA) was administered daily at 5 or 15 mg/kg via intraperitoneal injections. 12-week old male CD-1 252 253 (outbred) mice (Charles River, USA), 12-week old male C57BL/6J mice (Jackson Laboratory) and 8- and 18-month old male C57BL/6N mice (National Institute on Aging; NIA) were obtained. All 254 mice were fed either a HFD (60% calories from fat) or matching control diet (Research Diets, 255 USA, #D12492 and D12450J, respectively). NIA mice were sufficiently acclimated for 4 months 256 257 in our vivarium until they were considered middle-aged (12 mo.) and old (22 mo.) at the start of MOTS-c injections. Body weight and food consumption were recorded daily, while body 258 composition was analyzed twice weekly using an LF90II time-domain NMR minispec (Bruker, 259 USA). After eight weeks of injections (23.5 months of age), mice were transitioned to receive 260 MOTS-c injections three times weekly. No live mouse was censored. 261

262

263 <u>Physical Tests in Mice</u>

Running Test: Prior to running training/testing, mice were acclimated to the stationary treadmill 264 apparatus (TSE-Systems, USA) for ten minutes on two consecutive days (Days 1 and 2). Both the 265 266 high intensity test and training protocols were adapted from previously published protocols (52). Running training was given twice on non-consecutive days and consisted of a fixed speed run of 267 268 10 m/min for 20 minutes (Days 4 and 6) on a level treadmill. The treadmill test on Day 10 consisted 269 of three stages. Stage one was a five-minute run at 13 m/min. For the next five minutes, the speed 270 was increased by 1 m/min. The mice run at a fixed speed of 18 m/min for the next 30 minutes. Finally, after 40 minutes of total run time, the running speed is increased to 23 m/min until 271 exhaustion is reached. All training and testing were done on a level treadmill. Mice resting on the 272 platform were gently prodded to encourage re-engagement. Any mouse that resisted prodding and 273 remained on the platform for 30 seconds was considered to be exhausted, and time was recorded. 274

Walking Test: When the mice reached 30 months of age, they were no longer capable of performing
the same treadmill routine. We developed a measure of mobility in the aged mice consisting of a

60 second walking test. The treadmill was set at 13 m/min for 60 seconds. We recorded whether
the mouse was able to walk, or not, on the treadmill for 60 seconds, with gentle prodding as needed.
Mice remaining on the stationary platform, refusing to engage in the treadmill walking, for more
than five seconds were considered to have failed the test.

Rotarod: The Rotarod test was performed by placing the mice on the apparatus (TSE-Systems), all facing the opposite direction of rotation. The initial speed of rotation was 24 rpm and accelerated at 1 rpm every 10 seconds. Time to fall was recorded for each mouse, and three trials per mouse was run. Mice received no less than five minutes of recovery time between trials.

Grip Strength: We measured grip strength using a horizontal bar connected to the grip strength meter (TSE-Systems) as a high precision force sensor for the forelimbs. After allowing the mouse to properly grip the bar they were firmly and quickly pulled in the opposite direction. Only trials where the mouse released its paws from the bar simultaneously were counted as successful. Mice underwent three trials, with at least 30 seconds recovery time between trials.

Gait Analysis: To perform gait analysis, we applied a different color of non-toxic ink (BLICK®, USA) to the front and hind paw of the mice to record footprints. Barriers were constructed to guide the mice to walk straight on the recording paper. The home cage was kept at the end of the recording paper to encourage completion of the test. Only trials in which the mouse made a continuous, direct path to its home cage were counted. Stride length was measured as the average forward movement of three full strides as previously described(*53*).

296 *Cognitive tests*:

Y-maze tests were performed as previously described (54). Briefly, mice were placed in a maze consisting of three arms equally spaced 120° apart. Mice were placed in one arm of the maze and allowed to freely explore the maze for five minutes. Total arm entries and arm choices were recorded for each mouse. An arm entry was defined as a mouse having both front and hind paws entering the arm fully. Percent alternations was defined as an arm choice differing from the previous two compared to the total number of alternation opportunities.

Barnes maze tests were performed as previously described (*54*). 12-week old male CD-1 mice were tested twice daily for 7 days. Mice were placed in a start chamber in the middle of the maze and allowed to habituate (30 seconds), then the mouse was released to explore the maze and find the escape box (EB). Latency (time to enter the EB) and number of errors (nose pokes and head
deflections over false holes) were recorded. A maximum of 2 minutes was allowed for each trial.

308

309 In Vivo Metabolism Assessment

Metabolic Cages: Metabolic activity in mice was measured using the PhenoMaster system (TSE-310 311 Systems) equipped to detect indirect calorimetry, measure food and water intake, and monitor 312 activity. Prior to metabolic analysis, mice were housed 3-4 per cage in a facility with a 12:12 hour light- dark cycle (light period 0600-1800) at 24°C. Food and water were available *ad libitum*. For 313 metabolic assessment, nice were moved into individual PhenoMaster cages in an isolated room 314 under the same environmental conditions. Mice were automatedly monitored for 36 hours to record 315 physiological parameters. To measure O₂ intake and CO₂ production, gas sensors were calibrated 316 prior to the study using primary gas standards of known concentrations of O₂, CO₂, and N₂. Room 317 air was passed through the animal chambers at a rate of 0.5 L/min. Exhaust air from individual 318 cages were sampled at 30-minute intervals for 3 minutes. Sample air was passed through sensors 319 to determine oxygen consumption (VO_2) and carbon dioxide production (VCO_2) . The respiratory 320 exchange ratio (RER) was calculated as the ratio of carbon dioxide produced to oxygen 321 consumption. The PhenoMaster system allows for activity monitoring using a triple beam IR 322 technology system. Breaking the IR beams through movement was considered a "count". The 323 324 three-beam system allows XYZ monitoring that considers both ambulatory activity around the 325 cage as well as rearing activity. All data are expressed as the mean of three 24-hour acquisition 326 cycles.

Blood glucose: Blood was collected via a single tail-nick and immediately analyzed using a glucometer (Freestyle, Abbott). Blood collection was performed by trained professionals and in accordance with the University of Southern California Institutional Animal Care and Use Committee.

331

332 <u>Western Blots</u>

Protein samples were lysed in 1% Triton X-100 (Thermo Fisher Scientific, USA, #21568-2500)

with 1 mM EDTA (Promega Life Sciences, USA, #V4231) and 100 mM Tris-HCl pH 7.5 (Quality

Biological, USA, #351-006-101) and protease inhibitors (Roche, Germany, #118636170001) and 335 sonicated using a Sonic Dismembrator (Fisher Scientific, USA). Samples were heated at 95°C for 336 337 five minutes. Samples were ran on 4-20% gradient tris-glycine gels (TGX; Bio-Rad, USA, #456-1104) and transferred onto 0.2 µM PVDF membranes (Bio-Rad #162-0184) using a Transblot 338 Turbo semi-dry transfer system (Bio-Rad) at 9 volts for 15 minutes. Membranes were blocked for 339 1 hour using 5% BSA (Akron Biotech, USA, #AK8905-0100) in tris-buffered saline containing 340 0.05% Tween-20 (Bio-Rad #161-0781) and incubated in primary antibodies against MOTS-c 341 (rabbit polyclonal; YenZym, USA) and GAPDH (cat# 5174; Cell Signaling, USA) overnight at 342 4°C. Secondary HRP-conjugated antibodies (#7074; Cell Signaling, USA) were then added 343 (1:30,000) for one hour at room temperature. Chemiluminescence was detected and imaged using 344 Clarity western ECL substrate (Bio-Rad #1705060) and Chemidoc XRS system (Bio-Rad). 345 346 Western blots were quantified using ImageJ version 1.52k.

347

348 <u>Cell Studies</u>

349 Cell culture: C2C12 cells were cultured in DMEM with 4.5 g/L glucose (Corning, USA #10-017-

CV) and 10% FBS (Millipore-Sigma, USA, #F0926-500). All cells were stored at 37°C and 5%

- 351 CO₂. Cells were passaged when they reached 75-80% confluence using TrypLE (Thermo Fisher
- 352 Scientific #12605-010).

Cell survival assays: Protection against glucose restriction (GR) and serum deprivation (SD) was 353 354 tested by culturing cells in DMEM (Thermo Fisher Scientific #11966-025) with 0.5 g/L glucose (Millipore-Sigma #G8769) and 1% FBS. MOTS-c (10µM) or vehicle (PBS). MOTS-c (10µM) 355 356 was added to the media every 24 hours. After 48 hours of GR/SD, we performed crystal violet (Thermo Fisher Scientific #C581-25) staining as before (15) to determine cell survival. We also 357 tested cellular proliferation, following prolonged (7-day) GR/SD (DMEM with 1% FBS and 0.5 358 g/L glucose), as a measure of cellular fitness. In this case, MOTS-c-containing (10µM) media was 359 360 changed once every two days; no additional MOTS-c supplementation was given between media changes. After 7 days of GR/SD, we returned the cells to full growth media (10% FBS and 4.5 g/L 361 glucose) for 48 hours with MOTS-c (10µM), then stained them with crystal violet. To determine 362 the metabolic flexibility to utilize fatty acids, we cultured cells in DMEM with 1% FBS, 0.5 g/L 363

bioRxiv preprint doi: https://doi.org/10.1101/2019.12.22.886432; this version posted August 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

364 glucose, and 1% chemically defined lipid mixture (Millipore-Sigma #L0288) for 48 hours, then
365 stained them with crystal violet.

Metabolic flux: Real-time oxygen consumption and extracellular acidification rates in C2C12
myoblasts treated with 16% palmitate-BSA (1mM palmitate conjugated to 0.17mM BSA) or 16%
BSA (0.17 mM; Seahorse Bioscience #102720-100) were obtained using the XF96 Bioanalyzer
(Seahorse Bioscience) at the USC Leonard Davis School of Gerontology Seahorse Core. All values
were normalized to relative protein concentration using a BCA protein assay kit (Thermo Fisher
Scientific #23227).

Confocal microscopy: Confocal images were obtained using a Zeiss Confocal Laser Scanning 372 Microscope 700 (Zeiss, Germany). C2C12 myoblasts were cultured on glass coverslips 373 (Chemglass, USA, #CLS-1760-015). Cells were treated with FITC-MOTS-c (New England 374 375 Peptide) for either 0 hours (immediate), 30 minutes, 4 hours, or 24 hours. Some cells were left as untreated controls (data not shown). All cells were treated with Hoeschst (Biotium, USA, #40045) 376 for 15 minutes and then washed three times with PBS. Cells were fixed in 10% formalin 377 (Millipore-Sigma #EM-R04586-82) and washed an additional three times in PBS. Coverslips were 378 379 affixed to glass slides (VWR, USA, #48300-025) using ProLong Gold antifade reagent (Life 380 Technologies Corporation, USA, #P36934).

381

382 <u>Human Studies</u>

383 Study outline:

Participants gave written consent before the commencement of the study, which was approved by the Northern Health and Disability Ethics Committee (New Zealand) (16/STH/116/AM01). 10 sedentary (<4h aerobic exercise/week) healthy young males (24.5 ± 3.7 years old and BMI 24.1 \pm 2.1) were recruited to take part in a two-visit exercise trial. Recruited participants were free of cardiovascular, metabolic and blood diseases and were not taking any medication or supplements. The trial was separated into two visits, each involving exercise bouts that were carried out on an electromagnetically braked cycle ergometer (Velotron, RacerMate, USA). 391 Determination of peak oxygen uptake (VO₂peak) and maximal power output (visit 1): Peak oxygen 392 uptake was determined using a ramped cycling exercise protocol. Prior to testing, participants 393 warmed up for five minutes at a self-selected workload between 60 and 80W. The ramp protocol 394 began at 60W, with the cycling power output set to increase by 1W every 4 seconds (15W/min) 395 continuously until the participant was unable to maintain cycling workload (cycling 396 cadence<minimum 60 revolutions per minute) or maximal volitional fatigue was reached. Mean 397 Peak oxygen uptake of participants was reported as 38.4 ± 7.3 ml.kg.min.

398 Acute high intensity cycling exercise session (visit 2): Prior to visit 2, participants were asked to fast overnight (from 10PM) and were instructed to abstain from physical activity for at least 48h 399 400 prior. Upon arrival to the laboratory, participants lay supine for 15-minutes and then had an intravenous cannula inserted into a forearm vein. A resting plasma sample was collected followed 401 402 by a pre-exercise muscle biopsy taken from the vastus lateralis muscle (quadriceps muscle). Approximately 10-minutes later, participants completed ten, 60-second cycling intervals at 403 individually-specified peak power workloads (determined from peak oxygen uptake test) followed 404 by 75-seconds of rest/low intensity cycling (<30W) per interval as previously described (55). A 405 406 mid-exercise blood sample was taken following the completion of the 5th exercise interval as well as immediately following the completion of the exercise bout. In addition, an immediately-post 407 exercise muscle biopsy was taken (within ~5-minutes of completion of the exercise bout). 408 Participants remained supine and resting in the procedure bed for a 4-hour recovery period. 409 Following four-hours of recovery, a final blood and muscle biopsy sample was collected. 410

Muscle biopsy and blood sampling: Muscle biopsies were extracted under local anesthesia (1% 411 412 xylocaine) using the Bergstrom needle with manual suction technique (56). Biopsies were snapfrozen in liquid nitrogen and stored at -80°C until analyzed. Blood was drawn through a 20-gauge 413 cannula, collected in 10-mL EDTA vacutainers and then centrifuged immediately upon collection 414 at 4°C at 2,000 g for 10 minutes. Plasma was extracted and then stored at -80°C until further 415 416 analysis using an in-house ELISA as described before (13). Human skeletal muscle was processed for western blotting by soaking the samples in lysis buffer (above) and minced using a razor blade. 417 Once the sample was evenly minced, we proceeded with the Sonic Dismembrator step as described 418 above. 419

420

421 Liquid Chromatography-Mass Spectrometry Metabolomics

422 Metabolites were extracted from randomly selected tissue samples by adding 1 mL of 80:20 423 methanol:water solution on dry ice. Samples were incubated at -80C for 4 hours and centrifuged 424 at 4C for 5 minutes at 15k rpm. Supernatants were transferred into LoBind Eppendorf 425 microcentrifuge tubes and the cell pellets were re-extracted with 200 μL ice-cold 80% MeOH, 426 spun down and the supernatants were combined. Metabolites were dried at room temperature under 427 vacuum and re-suspended in water for injection.

Samples were randomized and analyzed on a Q-Exactive Plus hybrid quadrupole-Orbitrap mass 428 spectrometer coupled to an UltiMate 3000 UHPLC system (Thermo Scientific). The mass 429 spectrometer was run in polarity switching mode (+3.00 kV/-2.25 kV) with an m/z window ranging 430 from 65 to 975. Mobile phase A was 5 mM NH4AcO, pH 9.9, and mobile phase B was acetonitrile. 431 Metabolites were separated on a Luna 3 μ m NH2 100 Å (150 \times 2.0 mm) column (Phenomenex). 432 The flowrate was 300 µl/min, and the gradient was from 15% A to 95% A in 18 min, followed by 433 an isocratic step for 9 min and re-equilibration for 7 min. All samples were injected twice for 434 technical duplicates. Metabolites were detected and quantified as area under the curve based on 435 retention time and accurate mass (≤ 5 ppm) using the TraceFinder 3.3 (Thermo Scientific) 436 software. 437

438

439 <u>RNA-seq</u>

RNA purification from tissue and cells: Total RNA extraction from skelatal muscle tissue or
C2C12 mouse myoblasts was done using TRI Reagent (Millipore-Sigma #T9424). Muscle tissue
samples were flash-frozen in liquid nitrogen until further processing. Tissues were resuspended in
600µL of TRI Reagent, then homogenized on Lysing Matrix D 2mL tubes (MP Biomedicals) on
a BeadBug homogenizer (Benchmark Scientific). For both skeletal muscle and C2C12 cells, total
RNA was purified using the Direct-zol RNA MiniPrep (Zymo Research #R2052).

RNA-seq library preparation: Total RNA was subjected to rRNA depletion using the NEBNext
rRNA Depletion Kit (New England Biolabs), according to the manufacturer's protocol. Strand
specific RNA-seq libraries were then constructed using the SMARTer Stranded RNA-Seq Kit
(Clontech # 634839), according to the manufacturer's protocol. Based on rRNA-depleted input

amount, 13-15 cycles of amplification were performed to generate RNA-seq libraries. Paired-end
150bp reads were sent for sequencing on the Illumina HiSeq-Xten platform at the Novogene
Corporation (USA). The raw sequencing data was deposited to the NCBI Sequence Read Archive
(accession: PRJNA556045). The resulting data was then analyzed with a standardized RNA-seq
data analysis pipeline (described below).

455 *RNA-seq analysis pipeline*: To avoid the mapping issues due to overlapping sequence segments in paired end reads, reads were hard trimmed to 75bp using the Fastx toolkit v0.0.13. Reads were 456 then further quality-trimmed using Trimgalore 0.4.4 (github.com/FelixKrueger/TrimGalore) to 457 retain high-quality bases with Phred score > 20. All reads were also trimmed by 6 bp from their 5' 458 459 end to avoid poor qualities or biases. cDNA sequences of protein coding and lincRNA genes were obtained through ENSEMBL Biomart for the GRCm38 build of the mouse genome (Ensemble 460 461 release v94). Trimmed reads were mapped to this reference using kallisto 0.43.0-1 and the -frstranded option (57). All subsequent analyses were performed in the R statistical software 462 (https://cran.r-project.org/). 463

Read counts were imported into R, and summarized at the gene level, to estimate differential geneexpression as a function of age.

Because of high sample variability, we used surrogate variable analysis to remove experimental
noise from the muscle RNA-seq dataset (58). R package 'sva' v3.24.4 (59) was used to estimate
surrogate variable, and the effects of surrogate variables were regressed out using 'limma'.
Corrected read counts were then used for downstream analyses.

DEseq2 normalized fold-changes were then used to estimate differential gene expression between control and MOTS-c treated muscle or cell samples using the 'DESeq2' R package (DESeq2 1.16.1)(*60*). The heatmap of expression across samples for significant genes (Fig. 4G) was plotted using the R package 'pheatmap' 1.0.10 (Raivo Kolde, 2015-12-11; <u>https://CRAN.R-</u> project.org/package=pheatmap). Putative protein-protein interaction was derived using the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database version 11.0 (*61*) (https://string-db.org/).

- 477
- 478

bioRxiv preprint doi: https://doi.org/10.1101/2019.12.22.886432; this version posted August 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

479 <u>Functional enrichment analysis</u>

To perform functional enrichment analysis, we used the Gene Set Enrichment Analysis paradigm through its implementation in the R package 'ClusterProfiler' v3.10.1 (*62*), and Bioconductor annotation package 'org.Mm.eg.db' v3.7.0. Balloon plots representing the output were generated using R packages 'ggplot2' v3.1.0 and 'scales' 1.0.0.

484

485 <u>Principal Component Analysis</u>

Metabolites: Principal component analysis (PCA) was performed using the mean-centered matrix 486 of metabolite values per each mouse. Principal components that separated sample groups were 487 identified with visual inspection. Loadings from principal components that stratify experimental 488 samples versus controls were then queried against metabolic pathways using a Kolmogorov-489 Smirnov statistic against the expected distribution of metabolites. Metabolic pathway enrichment 490 analysis (gene set enrichment analysis, GSEA) (63) were performed using 28 metabolic pathways 491 defined by the Kyoto Encyclopedia of Genes and Genomes (KEGG) database using pathways with 492 four or more measured metabolites. 493

RNA-seq: PCA was performed using the R base package function 'prcomp'. The first 2 principal
components were used.

496

497 <u>Quantification and Statistical Analysis</u>

498 Unless otherwise noted, statistical significance was determined using the Student *t*-test. Statistical 499 tests were performed using GraphPad Prism version 8.1.2. Results of *t*-tests are indicated in all 500 figures as p<0.05, p<0.01, p<0.01, p<0.01 and *ns* for not significant (p>0.05).

501 The RNA-seq analytical code will be made available on the Benayoun lab github 502 (https://github.com/BenayounLaboratory/MOTSc_Exercise).

503

504

505

506 Figure Legends:

Fig. 1. MOTS-c responds to and regulates exercise in young subjects. (A) Schedule of exercise
on a stationary bicycle and blood and skeletal muscle collection in young male subjects (n=10).
(B, C) Representative western blot of MOTS-c from skeletal muscle and quantification (D)
Quantification of serum MOTS-c levels by ELISA. Data expressed as mean +/- SEM. Wilcoxon
matched-pairs signed rank test was used for (C, D).

512

Fig. 2. MOTS-c treatment increases physical capacity in young mice regardless of diet. (A-513 514 C) Treadmill performance of 12-week old male CD-1 (outbred) mice fed a normal diet (n=5-6); (A) running curves, (B) total time on treadmill, (C) total distance ran, and (D) percent capable of 515 reaching the highest speed (sprint). (E-H) Treadmill performance of 12-week old male C57BL/6J 516 (inbred) mice fed a HFD (n=8); (E) running curves, (F) total time on treadmill (G) total distance 517 518 ran (H) percent capable of reaching the highest speed (final stage). (I) PCA and MSEA on metabolomic data from skeletal muscle and liver of C57BL/6J mice that were fed a HFD, treated 519 with MOTS-c, and exercised. Data expressed as mean +/- SEM. Log-rank (Mantel-Cox) test was 520 used for (A, E). Otherwise, all statistics were performed using the Student's *t*-test. **P*<0.05, ** 521 *P*<0.01, *** *P*<0.001. 522

523

Fig. 3. Acute MOTS-c treatment enhances physical capacity in old mice. (A) Schedule of 524 MOTS-c treatment and assays in middle-aged and old C57BL/6N mice (n=10 and 16-19, 525 respectively), including (**B**) treadmill running curves, (**C**) total time on treadmill, (**D**) total distance 526 ran on treadmill, and (E) percent capable of reaching the highest speed on a treadmill (final stage). 527 (F) Respiratory exchange ratio (RER) following 2 weeks of daily MOTS-c injection (n=4). (G, H) 528 Skeletal muscle from treadmill-exercised old mice (22.5 months) treated daily with MOTS-c (15 529 mg/kg/day) for 2 weeks (n=10) were subject to (G) metabolomics and analyzed using PCA and 530 MSEA and (H) GSEA analysis of muscle RNA-seq analysis. Balloon plots of select enriched terms 531 using Gene Ontology Biological Process (GO BP) database at false discovery rate (FDR) < 15%. 532 Full GSEA results are available in table S1. Data expressed as mean +/- SEM. Log-rank (Mantel-533 Cox) test was used for (B) and two-way ANOVA (repeated measures) was used for (F). GSEA 534

statistics from R package 'clusterProfiler' were used for (**H**). Otherwise, all statistics were performed using the Student's *t*-test. *P<0.05, ** P<0.01, *** P<0.001.

537

538 Fig. 4. MOTS-c regulates aging metabolism and healthspan. Life-long measurements on male C57BL6/N mice treated intermittently (3x/week) with MOTS-c (15 mg/kg/day) starting at middle 539 540 and old age (13.5 and 23.5 mo.) as described in Fig. 2a (n=16-19). (A) grip strength test (n=11), 541 (B) gait analysis (stride length) (n=5), (C) 60-second walking test (n=11-12), and (D) blood glucose levels (n=11). (E, F) Body weight (E) as a function of time and (F) the total sum (Σ) ; (G, 542 **H**) Food intake (**G**) as a function of time and (**H**) the total sum (Σ); (**I**, **J**) Percent fat mass (**I**) as a 543 544 function of time and (J) the total sum (Σ); (K, L) Percent lean mass (K) as a function of time and (L) the total sum (Σ). (M) Lifespan curve; P=0.05 until 31.8 months of age. Overall curve trended 545 towards increased median and maximum lifespan (P=0.23). Data expressed as mean +/- SEM. 546 Log-rank (Mantel-Cox) test was used for (M). Otherwise, all statistics were performed using the 547 Student's *t*-test. **P*<0.05, ** *P*<0.01, *** *P*<0.001. 548

549

Fig. 5. MOTS-c regulates myoblast gene expression and enhances adaptation to metabolic 550 551 stress. (A-C) Survival of MOTS-c-treated (10μ M; equal-volume vehicle control) C2C12 myoblasts assessed by crystal violet staining following (A) 48 hours of glucose restriction (GR; 552 553 0.5 g/L) and serum deprivation (SD; 1% FBS) with MOTS-c treated only once initially (n=12), (B) 7 days of GR/SD with daily MOTS-c treatment, followed by a 2-day recovery in full media 554 555 with MOTS-c (n=10), and (C) 48 hours of complete GR (0 g/L) with chemically-defined lipid supplementation and daily MOTS-c treatment (n=6). (D) Real-time oxygen consumption rate 556 557 (OCR) in response to fatty acid (palmitate-BSA) in C2C12 myoblasts treated with MOTS-c (10µM) for 48 hours (n=11-12). (E) Time-dependent subcellular localization pattern of 558 exogenously treated MOTS-c-FITC (10µM) in C2C12 myoblasts. Scale bar: 10µm. (F-I) RNA-559 seq was performed on C2C12 myoblasts following 48 hours of GR/SD with/without a unique 560 initial MOTS-c (10 μ M) treatment (n=6). (F) Principle Component Analysis (PCA) and (G) 561 562 heatmap of significantly differentially regulated genes by MOTS-c at false discovery rate (FDR) < 5% by DESeq2 analysis. (H) Protein-protein interaction network analysis based on genes that 563 were significantly differentially regulated by MOTS-c (FDR < 5%) using the STRING (Search 564

Tool for the Retrieval of Interacting Genes/Proteins) database version 11.0 (*61*). (I) Balloon plots
of common biological processes derived from RNA-seq data between MOTS-c-treated (i) skeletal
muscle from old mice (see Fig. 2) and (ii) C2C12 myoblasts, based on gene set enrichment analysis
(GSEA) using gene ontology biological process (GO_BP) (select gene sets; FDR < 15%). Data

569 expressed as mean +/- SEM. Student's *t*-test. **P*<0.05, ** *P*<0.01, *** *P*<0.001

570

Acknowledgments: We thank the USC Leonard Davis School of Gerontology Mouse 571 Phenotyping core and Seahorse Bioanalyzer core and the USC Genomics core for experimental 572 assistance. Funding was provided by the American Federation for Aging Research (AFAR), the 573 574 National Institute on Aging (T32 AG052374) and the USC Manning Endowed Fellowship to 575 J.C.R., a Mork Graduate Fellowship from the USC Viterbi School of Engineering to J.H.J., the USC Viterbi School of Engineering to N.A.G., the NIA (P01AG034906) to P.C., the NIA 576 (R00AG049934), an innovator grant from the Rose Hills foundation, a seed grant the NAVIGAGE 577 foundation, and the Hanson-Thorell Family to B.A.B., Rutherford Discovery Fellowship and a 578 579 Marsden Fund Fast Start Grant to T.L.M., and the NIA (R01AG052258), Ellison Medical Foundation (EMF), AFAR, and the Hanson-Thorell Family to C.L. 580

581

Author contributions: J.C.R., T.L.M., B.A.B., P.C., N.A.G., D.C-S., and C.L. conceived the
experiments. J.C.R., J.S.T.W., B.A.B., R.L., R.W.L., J.H.J., C.J.M., and D.C-S. performed
experiments. J.C.R., T.L.M., J.S.T.W., B.A.B., R.L., R.W.L., P.C., N.A.G., J.H.J., and C.L.
analyzed the data. J.C.R. and C.L. wrote the manuscript.

586

587 Competing interests: P.C. and C.L. are consultants and shareholders of CohBar, Inc. All other588 authors declare no competing interests.

589

590 Data and materials availability: All data are available in the main manuscript and Extended Data
591 material. RNA-seq data have been uploaded to the NCBI SRA database (accession:
592 PRJNA556045).

593

594 **References:**

- C. Lopez-Otin, M. A. Blasco, L. Partridge, M. Serrano, G. Kroemer, The hallmarks of aging. *Cell* **153**, 1194-1217 (2013).
- C. Lopez-Otin, L. Galluzzi, J. M. Freije, F. Madeo, G. Kroemer, Metabolic Control of Longevity. *Cell* 166, 802-821 (2016).
- 599 3. A. Bratic, N. G. Larsson, The role of mitochondria in aging. *J Clin Invest* **123**, 951-957 (2013).
- S. Hill, H. Van Remmen, Mitochondrial stress signaling in longevity: A new role for mitochondrial
 function in aging. *Redox biology* 2, 936-944 (2014).
- Martin B. Jensen, H. Jasper, Mitochondrial Proteostasis in the Control of Aging and Longevity.
 Cell metabolism 20, 214-225 (2014).
- 604 6. Y. Wang, S. Hekimi, Mitochondrial dysfunction and longevity in animals: Untangling the knot. 605 *Science* **350**, 1204-1207 (2015).
- 6067.T. E. S. Kauppila, J. H. K. Kauppila, N.-G. Larsson, Mammalian Mitochondria and Aging: An607Update. *Cell metabolism* **25**, 57-71 (2017).
- 6088.J. Y. Jang, A. Blum, J. Liu, T. Finkel, The role of mitochondria in aging. J Clin Invest 128, 3662-3670609(2018).
- 9. P. M. Quirós, A. Mottis, J. Auwerx, Mitonuclear communication in homeostasis and stress. *Nature Reviews Molecular Cell Biology* 17, 213-226 (2016).
- J. Durieux, S. Wolff, A. Dillin, The cell-non-autonomous nature of electron transport chain mediated longevity. *Cell* 144, 79-91 (2011).
- 614 11. C. Lee, K. Yen, P. Cohen, Humanin: a harbinger of mitochondrial-derived peptides? *Trends in*615 *endocrinology and metabolism: TEM*, (2013).
- 616 12. S.-J. Kim, J. Xiao, J. Wan, P. Cohen, K. Yen, Mitochondrially derived peptides as novel regulators
 617 of metabolism. *The Journal of Physiology* 595, 6613-6621 (2017).
- 618 13. C. Lee *et al.*, The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and
 619 reduces obesity and insulin resistance. *Cell Metab* 21, 443-454 (2015).
- K. Zarse, M. Ristow, A mitochondrially encoded hormone ameliorates obesity and insulin
 resistance. *Cell Metab* 21, 355-356 (2015).
- K. H. Kim, J. M. Son, B. A. Benayoun, C. Lee, The Mitochondrial-Encoded Peptide MOTS-c
 Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic
 Stress. *Cell metabolism* 28, 516-524 e517 (2018).
- K. C. Mangalhara, G. S. Shadel, A Mitochondrial-Derived Peptide Exercises the Nuclear Option. *Cell Metab* 28, 330-331 (2018).
- 627 17. W. Wong, Going nuclear with stress. *Science Signaling* **11**, (2018).
- 62818.P. P. Singh, B. A. Demmitt, R. D. Nath, A. Brunet, The Genetics of Aging: A Vertebrate629Perspective. *Cell* **177**, 200-220 (2019).
- 630 19. L. Fontana, L. Partridge, V. D. Longo, Extending healthy life span--from yeast to humans. *Science*631 **328**, 321-326 (2010).
- 632 20. B. K. Kennedy *et al.*, Geroscience: Linking Aging to Chronic Disease. *Cell* **159**, 709-713 (2014).
- 533 21. J. Campisi *et al.*, From discoveries in ageing research to therapeutics for healthy ageing. *Nature*571, 183-192 (2019).
- 635 22. D. E. Gottschling, T. Nyström, The Upsides and Downsides of Organelle Interconnectivity. *Cell*636 169, 24-34 (2017).
- 637 23. O. Matilainen, P. M. Quirós, J. Auwerx, Mitochondria and Epigenetics Crosstalk in Homeostasis
 638 and Stress. *Trends in Cell Biology* 27, 453-463 (2017).
- 639 24. M. Ramanjaneya *et al.*, Mitochondrial-Derived Peptides Are Down Regulated in Diabetes
 640 Subjects. *Frontiers in Endocrinology* **10**, (2019).


C 4 4	25	C. O. V. Venes, D. J. Tang, A. Mitashandwiel Francisch Massenner et the Nucleus, Colle 7, (2010)
641	25.	C. Q. Y. Yong, B. L. Tang, A Mitochondrial Encoded Messenger at the Nucleus. <i>Cells</i> 7 , (2018).
642	26.	R. Alis, A. Lucia, J. R. Blesa, F. Sanchis-Gomar, The role of mitochondrial derived peptides (MDPs)
643	27	in metabolism. <i>Journal of cellular physiology</i> 230 , 2903-2904 (2015).
644	27.	S. Li, I. Laher, Exercise Pills: At the Starting Line. <i>Trends in pharmacological sciences</i> , (2015).
645	28.	A. Knoop, A. Thomas, M. Thevis, Development of a mass spectrometry based detection method
646		for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.
647	20	Rapid Commun Mass Spectrom 33 , 371-380 (2019).
648	29.	B. H. Goodpaster, L. M. Sparks, Metabolic Flexibility in Health and Disease. <i>Cell Metabolism</i> 25 ,
649		1027-1036 (2017).
650	30.	R. L. Smith, M. R. Soeters, R. C. I. Wüst, R. H. Houtkooper, Metabolic Flexibility as an Adaptation
651		to Energy Resources and Requirements in Health and Disease. <i>Endocrine Reviews</i> 39 , 489-517
652		(2018).
653	31.	N. Barzilai, J. P. Crandall, S. B. Kritchevsky, M. A. Espeland, Metformin as a Tool to Target Aging.
654		<i>Cell Metabolism</i> 23 , 1060-1065 (2016).
655	32.	M. Kaeberlein, P. S. Rabinovitch, G. M. Martin, Healthy aging: The ultimate preventative
656		medicine. <i>Science</i> 350 , 1191-1193 (2015).
657	33.	N. L. Nadon, R. Strong, R. A. Miller, D. E. Harrison, NIA Interventions Testing Program:
658		Investigating Putative Aging Intervention Agents in a Genetically Heterogeneous Mouse Model.
659		EBioMedicine 21 , 3-4 (2017).
660	34.	D. E. Harrison et al., Rapamycin fed late in life extends lifespan in genetically heterogeneous
661		mice. <i>Nature</i> 460 , 392-395 (2009).
662	35.	K. Mao et al., Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in
663		female mice. Nature Communications 9, (2018).
664	36.	P. D. Neufer et al., Understanding the Cellular and Molecular Mechanisms of Physical Activity-
665		Induced Health Benefits. Cell Metab 22, 4-11 (2015).
666	37.	L. R. Cataldo, R. Fernandez-Verdejo, J. L. Santos, J. E. Galgani, Plasma MOTS-c levels are
667		associated with insulin sensitivity in lean but not in obese individuals. J Investig Med 66, 1019-
668		1022 (2018).
669	38.	C. Du et al., Circulating MOTS-c levels are decreased in obese male children and adolescents and
670		associated with insulin resistance. Pediatr Diabetes, (2018).
671	39.	Q. Li et al., Earlier changes in mice after D-galactose treatment were improved by mitochondria
672		derived small peptide MOTS-c. Biochemical and biophysical research communications, (2019).
673	40.	H. Lu et al., MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced
674		metabolic dysfunction. J Mol Med (Berl), (2019).
675	41.	M. Ramanjaneya et al., Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in
676		PCOS and healthy subjects. Clinical Endocrinology, (2019).
677	42.	John, M. Hargreaves, Michael, Juleen, Integrative Biology of Exercise. <i>Cell</i> 159 , 738-749 (2014).
678	43.	B. Egan, Juleen, Exercise Metabolism and the Molecular Regulation of Skeletal Muscle
679		Adaptation. Cell metabolism 17, 162-184 (2013).
680	44.	L. Packer, E. Cadenas, K. J. A. Davies, Free radicals and exercise: An introduction. Free Radical
681		Biology and Medicine 44 , 123-125 (2008).
682	45.	T. L. Merry, M. Ristow, Do antioxidant supplements interfere with skeletal muscle adaptation to
683		exercise training? , n/a-n/a (2015).
684	46.	D. Chrétien et al., Mitochondria are physiologically maintained at close to 50 °C. PLOS Biology
685		16 , e2003992 (2018).
686	47.	S. J. Kim et al., The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites
687		and enhances insulin sensitivity. Physiological Reports 7, (2019).
688	48.	J. M. Son, C. Lee, Mitochondria: multifaceted regulators of aging. BMB Reports 52, 13-23 (2019).


E. M. Crimmins, Lifespan and Healthspan: Past, Present, and Promise. *The Gerontologist* 55, 901911 (2015).

- 691 50. H. Zempo *et al.*, Relation between type 2 diabetes and m. 1382 A> C polymorphism which
 692 occurs amino acid replacement (K14Q) of mitochondria-derived MOTS-c. *The FASEB Journal* **30**,
 693 956.951-956.951 (2016).
- 694 51. N. Fuku *et al.*, The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?
 695 *Aging Cell* 14, 921-923 (2015).
- 69652.A. Das *et al.*, Impairment of an Endothelial NAD(+)-H2S Signaling Network Is a Reversible Cause697of Vascular Aging. *Cell* **173**, 74-89 e20 (2018).
- 698 53. R. J. Carter, J. Morton, S. B. Dunnett, Motor coordination and balance in rodents. *Curr Protoc* 699 *Neurosci* Chapter 8, Unit 8 12 (2001).
- 54. S. Brandhorst *et al.*, A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration,
 Finhanced Cognitive Performance, and Healthspan. *Cell Metabolism* **22**, 86-99 (2015).
- 55. C. P. Hedges *et al.*, Peripheral blood mononuclear cells do not reflect skeletal muscle
 mitochondrial function or adaptation to high-intensity interval training in healthy young men. *J* Appl Physiol (1985) **126**, 454-461 (2019).
- 70556.J. Bergstrom, Percutaneous needle biopsy of skeletal muscle in physiological and clinical706research. Scand J Clin Lab Invest **35**, 609-616 (1975).
- 70757.N. L. Bray, H. Pimentel, P. Melsted, L. Pachter, Near-optimal probabilistic RNA-seq708quantification. *Nature Biotechnology* **34**, 525-527 (2016).
- 58. J. T. Leek, J. D. Storey, Capturing Heterogeneity in Gene Expression Studies by Surrogate Variable
 Analysis. *PLoS Genetics* 3, e161 (2007).
- 711 59. J. T. Leek *et al.*, sva: Surrogate Variable Analysis. R package version 3.32.1., (2019).
- 71260.M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-713seq data with DESeq2. Genome Biology 15, (2014).
- D. Szklarczyk *et al.*, STRING v11: protein–protein association networks with increased coverage,
 supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Research* 47, D607-D613 (2019).
- 717 62. G. Yu, L.-G. Wang, Y. Han, Q.-Y. He, clusterProfiler: an R Package for Comparing Biological
- Themes Among Gene Clusters. *OMICS: A Journal of Integrative Biology* **16**, 284-287 (2012).
- A. Subramanian *et al.*, Gene set enrichment analysis: A knowledge-based approach for
 interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences* **102**, 15545-15550 (2005).


722


bioRxiv preprint doi: https://doi.org/10.1101/2019.12.22.886432; this version posted August 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.






bioRxiv preprint doi: https://doi.org/10.1101/2019.12.22.886432; this version posted August 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.







Α

D

Ε




Fig. S1. MOTS-c levels in human muscle and plasma. MOTS-c levels mea- sured by (A) Western blotting on human skeletal muscle collected pre-, post-exercise and 4- hours of resting and (B) ELISA on plasma from same individuals collected pre-, mid-, post- exercise and 4-hours of resting (n=10). Statistics by Wilcox-on matched-pairs signed rank test. **P<0.01




Fig. S2. Rotarod, grip strength, and Barnes Maze tests in MOTS-c treated old mice. (**A**) Summary of latency time to fall on the Rotarod test (n=15). The speed of the rotations increased from a starting speed of 24 rpm by 1 rpm every 10 seconds. (**B**) grip strength test. (**C**,**D**) Barned Maze performance in control and MOTS-c treated 12-week old CD-1 mice (n=15). (**C**) There was no changes in average time to find the escape box (latency) between control and MOTS-c treated mice. (**D**) There was no change in the number of errors made prior to discovering the escape box between groups. Errors were defined as nose-pokes or head deflections over false holes. Data expressed as mean +/- SEM of three 24-hour acquisition cycles. Student's t-test. *P<0.05, **P<0.01, ***P<0.001.




Fig. S3. Outline of HFD mouse experiments. Timeline of experiment for 12-week old male CD-1 (outbred) and C57BL/6J (inbred) mice fed a HFD or defined control diet. (**A**) CD-1 mice were fed a HFD and given daily intraperitoneal injections (IP) of MOTS-c (0, 5, or 15 mg/kg/day) from Day 0. Treadmill running tests were performed on Day 7 (fig. S4a) and Day 10 (Fig. 1e-h). Daily MOTS-c injections ceased at Day 16. (**B**) C57BL/6J mice were started on either a HFD or a defined control diet on Day 0 and continued uninterruptedly throughout the experiment. Daily MOTS-c treatment (15 mg/kg; IP) started on Day 14. Treadmill running tests were performed on Day 24 and Day 28 (10 days and 14 days after the start of MOTS-c treatment) (Fig. 1i-l; fig. S4b). Mice were treated daily until Day 56, at which time metabolomics was performed (Fig. 1m).

bioRxiv preprint doi: https://doi.org/10.1101/2019.12.22.886432; this version posted August 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.




Fig. S4. Initial running time of MOTS-c-treated young mice. (**A**) Running time of CD-1 mice following seven days of MOTS-c treatment (n=5-6). MOTS-c (15 mg/kg/day) treatment showed a trend towards enhanced running performance. (**B**) Running time of HFD-fed C57BL/6J mice following 10 days of MOTS-c treatment (n=8). Data expressed as mean +/- SEM. Student's t-test. *P<0.05








Fig. S5. Body composition analysis on MOTS-c-treated young mice. Body composition was measured non-invasively using a time-domain NMR analyzer. (**A-C**) Young CD-1 mice were treated daily with MOTS-c (0, 5, or 15 mg/kg/day;IP) for 16 days (n=5-6) and percent (**A**) body weight, (**B**) fat mass, and (**C**) lean muscle mass were measured. (**D-F**) C57BL/6J mice either on a HFD or a defined control diet and treated daily with MOTS-c (15 mg/kg/day; IP) or saline control (n=8) and percent (**D**) body weight, (**E**) fat mass, and (**F**) lean muscle mass were measured the start of MOTS-c treatment. Data expressed as mean +/- SEM. Significance determined by using two-way ANOVA (repeated measures). *P<0.05, **P<0.01, ***P<0.001.









bioRxiv preprint doi: https://doi.org/10.1101/2019.12.22.886432; this version posted August 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.



Pathways (GSEA/GO_Biological Process)

signed enrichment 2.0 1.8 1.6 1.4 Pval (-Log10) • 1.0 • 1.2 • 1.4	leukocyte migration tumor necrosis factor superfamily cytokine production cytokine-mediated signaling pathway tumor necrosis factor production regulation of tumor necrosis factor production regulation of tumor necrosis factor production cellular response to tumor necrosis factor leukocyte differentiation cellular response to tumor necrosis factor leukocyte migration response to wounding wound healing inflammatory response positive regulation of leukocyte migration		Immune Response	carbohydrate catabolic process hexose metabolic process monosaccharide metabolic process regulation of cellular carbohydrate metabolic process carbohydrate metabolic process cellular carbohydrate metabolic process glucose metabolic process carbohydrate homeostasis glucose homeostasis regulation of carbohydrate metabolic process carbohydrate derivative biosynthetic process cellular response to insulin stimulus cellular glucose homeostasis response to insulin	Carbohydrate Metabolism
● 1.6	myeloid leukocyte migration negative regulation of defense response regulation of inflammatory response leukocyte differentiation negative regulation of immune system process regulation of response to wounding innate immune response defense response to other organism defense response to bacterium regulation of cytokine production negative regulation of immune response leukocyte cell-cell adhesion			regulation of lipid localization regulation of fat cell differentiation regulation of lipid biosynthetic process positive regulation of lipid metabolic process lipid biosynthetic process fatty acid metabolic process regulation of lipid metabolic process lipid catabolic process cellular response to lipid lipid localization lipid transport	Lipid Metabolism
	import into nucleus protein import into nucleus protein localization to nucleus nucleocytoplasmic transport nuclear transport regulation of protein localization to nucleus pyridine nucleotide metabolic process	•	Nuclear Transport	protein import alpha-amino acid metabolic process cellular amino acid metabolic process cellular response to nitrogen compound cellular modified amino acid metabolic process positive regulation of protein catabolic process positive regulation of cellular protein catabolic process regulation of protein catabolic process	Protein Metabolism
	nucleotide biosynthetic process ribose phosphate biosynthetic process nicotinamide nucleotide metabolic process pyridinecontaining compound metabolic process nucleoside phosphate biosynthetic process purine ribonucleotide biosynthetic process purine-containing compound biosynthetic process purine nucleotide biosynthetic process purine nucleotide biosynthetic process nucleotide biosynthetic process purine nucleotide biosynthetic process nucleotide metabolic process nucleotide metabolic process purine ribonucleoside triphosphate metabolic process purine nucleoside triphosphate metabolic process purine nucleoside triphosphate metabolic process			cellular respiration reactive oxygen species metabolic process energy derivation by oxidation of organic compounds regulation of reactive oxygen species metabolic process oxidoreduction coenzyme metabolic process mitochondrion organization response to oxidative stress response to oxygen levels response to oxygen levels cellular response to oxidative stress mitochondrial transport cellular response to reactive oxygen species	Oxidative Metabolism
	ribose phosphate metabolic process purine ribonucleoside triphosphate metabolic process ribonucleoside triphosphate biosynthetic process ribonucleoside triphosphate metabolic process purine ribonucleotide metabolic process purine –containing compound metabolic process purine nucleotide metabolic process nucleoside triphosphate biosynthetic process		Nucleotide Metabolism	generation of precursor metabolites and energy ATP biosynthetic process ATP metabolic process multicellular organismal homeostasis response to starvation response to nutrient levels tissue homeostasis cellular response to starvation	General Metabolism
	nucleoside monophosphate biosynthetic process nucleoside monophosphate metabolic process ribonucleoside monophosphate biosynthetic process ribonucleoside monophosphate biosynthetic process purine nucleoside monophosphate biosynthetic process purine ribonucleoside monophosphate biosynthetic process purine ribonucleoside monophosphate metabolic process			actin filament organization positive regulation of cytoskeleton organization regulation of actin cytoskeleton organization regulation of actin filament-based process regulation of supramolecular fiber organization regulation of actin filament organization skeletal system morphogenesis	Cytoskeletal Regulation
	purine nucleoside monophosphate metabolic process		1	protein folding angiogenesis muscle cell proliferation temperature homeostasis blood circulation	Misc. Processes

Fig. S8. Gene expression analysis on skeletal muscle from exercised MOTS-c-treated old mice. RNA-seq was performed on skeletal muscles from MOTS-c-treated old mice. Balloon plots of biological processes derived from Gene Set Enrichment Analysis (GSEA) using the Gene Ontology (Biological Process) database at a false discovery rate (FDR) < 15% (n=6).




Fig. S9. Rotarod and Y-Maze tests in MOTS-c-treated old mice. Middle-aged (14 mo.; n=5-6) and old (24 mo.; n=17-19) mice were treated daily with MOTS-c (15 mg/kg/day; IP) and subject to (**A**) a rotarod test and (**B**) Y- maze test. Data expressed as mean +/- SEM. Student's t-test. ***P<0.001.






Fig. S10. Total physical activity in MOTS-c-treated old mice. Total movement [horizontal and vertical movement (XYZ-axis)] of MOTS-c-treated (A) middle-aged (14 mo.) and (B) old (24 mo.) mice were continuously measured using metabolic cages throughout the day for three days (n=4). (C) The sum of all measured movements is shown. (D-F) The procedure was repeated on the same mice after 6 months of LLII MOTS-c treatment. Data expressed as mean +/- SEM of three 24-hour acquisition cycles. Student's t-test. *P<0.05, **P<0.01, ***P<0.001.





bioRxiv preprint doi: https://doi.org/10.1101/2019.12.22.886432; this version posted August 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.




Fig. S12. MOTS-c-dependent glycolytic rate in lipid-stimulated mouse myoblasts. C2C12 mouse myoblasts were treated with MOTS-c (10µM) or saline control in nutrient- limited media (n=11-12). Real-time glycolytic flux determined by the extracellular acidification rate was measured using the XF96 Seahorse bioanalyzer. Prior to the start of the assay, nutrient-deprived cells were given either BSA alone or palmitate bound to BSA (palmitate-BSA) to determine the capacity to metabolize fatty acids. Data expressed as mean +/- SEM. Student's t-test. *P<0.05, **P<0.01, ***P<0.001.

bioRxiv preprint doi: https://doi.org/10.1101/2019.12.22.886432; this version posted August 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/functor of the second author of the second a

		-	1
signed enrichment	protein folding	•	
	ribosome biogenesis	0	
- 2.4 - 2.2	response to topologically incorrect protein regulation of ubiquitin-dependent protein catabolic process		
2.0	rRNA processing	ŏ	
1.8	ribonucleoprotein complex biogenesis	ŏ	
1.6 1.4	mRNA processing	0	
	regulation of proteolysis involved in cellular protein catabolic process	\bigcirc	
	regulation of proteasomal protein catabolic process	\bigcirc	
	regulation of mRNA processing	0	
Pval (-Log10)	negative regulation of proteolysis	0	
-	proteasome-mediated ubiquitin-dependent protein catabolic process regulation of cellular protein catabolic process	0	
1.351.40	mRNA metabolic process	ŏ	
1.45	protein stabilization	õ	
-	RNA splicing	\bigcirc	
	RNA splicing, via transesterification reactions	\bigcirc	
	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	\bigcirc	Protein
	mRNA splicing, via spliceosome	0	/Translation
	regulation of mRNA metabolic process	0	(&)
	proteasomal protein catabolic process	0	Regulation /
	regulation of protein catabolic process rRNA metabolic process	0	
	RNA localization	õ	
	modification-dependent protein catabolic process	õ	
	ubiquitin-dependent protein catabolic process	\bigcirc	
	regulation of protein modification by small protein conjugation or removal	\bigcirc	
	regulation of protein ubiquitination	0	
	regulation of proteolysis	0	
	positive regulation of protein catabolic process	Ô	
	negative regulation of protein modification process negative regulation of phosphorylation	0	
	negative regulation of protein phosphorylation	Õ	
	positive regulation of establishment of protein localization	0	
	regulation of establishment of protein localization	\circ	
	proteolysis involved in cellular protein catabolic process	\bigcirc	
	outrissis apartatis signaling pathway	\bigcirc	1
	extrinsic apoptotic signaling pathway intrinsic apoptotic signaling pathway	0	
	regulation of intrinsic apoptotic signaling pathway	0	
	apoptotic signaling pathway	Õ	
	negative regulation of apoptotic signaling pathway	0	
	regulation of neuron death	\circ	Cell Death
	regulation of neuron apoptotic process	°	
	neuron death regulation of apoptotic signaling pathway	0	
	positive regulation of programmed cell death	0	
	positive regulation of apoptotic process	0	
	response to oxidative stress	\bigcirc	
	response to reactive oxygen species cellular response to oxidative stress	0	Oxidative Stress
	Central response to oxidative stress	0	
	nucleocytoplasmic transport	0	Nuclear Transport
	nuclear transport	0	
		0	1
	cellular response to hormone stimulus response to hormone	0	Response to Hormones
	cellular response to steroid hormone stimulus	0	
			1
	regulation of cellular catabolic process	0	
	modification-dependent macromolecule catabolic process	0	
	positive regulation of cellular catabolic process positive regulation of catabolic process	0	Misc. Catabolic Processes
	cellular nitrogen compound catabolic process	0	
	organic cyclic compound catabolic process	0	
	heterocycle catabolic process	٥	
		0	
	response to lipid negative regulation of phosphorus metabolic process	0	Misc. Metabolic Processes
	negative regulation of phosphorus metabolic process negative regulation of phosphate metabolic process	0	
			1

Fig. S13. Gene expression analysis on MOTS-c-treated mouse myoblasts under metabolic stress. RNA-seq was performed on C2C12 myoblasts following 48 hours of GR/SD with MOTS-c (10µM) treatment only once initially (n=6). Balloon plots of biological processes derived from Gene Set Enrichment Analysis (GSEA) using the Gene Ontology (Biological Process) database at a false discovery rate (FDR) < 15% (n=6).